Abstract:
A non-fermentation process for preparing a benzodiazepinedione of the formula: ##STR1## and intermediates are disclosed.

Description:
BACKGROUND OF THE INVENTION 
     This invention relates to a non-fermentation route to a benzodiazepinedione having cholecystokinin (CCK) inhibiting activity and a tryptophan derivative used as an intermediate. 
     The compound: ##STR2## is disclosed in published European application No. 116,150. This compound is active as a CCK inhibitor. The compound is shown to be prepared by fermentation. 
     A non-fermentation process for preparation of X using a tryptophan derivative as an intermediate has been discovered. 
     SUMMARY OF THE INVENTION 
     A tryptophan derivative of Formula A disclosed below. 
     DETAILED DESCRIPTION OF THE INVENTION 
     A compound of the formula: ##STR3## is prepared by (a) treating tryptophan with isatoic anhydride to obtain a compound of the formula: ##STR4## (b) treating A with Lawesson&#39;s Reagent to obtain a compound of the formula: ##STR5## (c) treating B with RI wherein R is lower alkyl (having 1-6 and preferably 1-3 carbon atoms) to obtain a compound of the formula: ##STR6## and (d) condensing C with ##STR7##  to obtain X. 
     The invention is embodied in the compound of Formula A. A preferred embodiment is the Formula A compound where the tryptophan moiety is derived from the L-isomer. 
     The following set of equations concisely illustrates the preparation of Compound A and its use in preparing Compound X. ##STR8## 
     Step (a): 
     The reaction of tryptophan with isatoic anhydride is generally carried out by suspending the reactants in an aqueous medium containing an amine base such as triethylamine and the like and stirring the mixture at room temperature for a period of time (16 hours). The water is removed, e.g. by vacuum, and an organic acid e.g. acetic acid is added. The mixture is refluxed for a period of time (4 to 5 hours). The product A is recovered in a conventional manner (cf M. Gates, J. Org. Chem., (1980) 45, 1675). 
     Step (b): 
     The A compound is treated with 2,4-bis(4-methoxyphenyl)-2,4-dithioxo-1,3,2,4-dithiaphosphetane (Lawesson&#39;s reagent) in a suitable reaction medium e.g. tetrahydrofuran (THF). This reaction is generally carried out at room temperature while protecting the mixture from moisture. The product B is then conventionally isolated from the reaction mixture. 
     Step (c): 
     The B compound is treated with an C 1  -C 4  arkyliodide e.g. CH 3  I in a suitable solvent system such as water-toluene containing a phase transfer catalyst such as tetra-n-butyl ammonium hydrogen sulfate and a base such as sodium or potassium hydroxide. The product C is conventionally recovered from this reaction mixture. 
     Step (d): 
     The C compound is condensed with anthranilic acid generally at elevated temperature (170° C. to about 180° C.). The X product is recovered conventionally from the reaction mixture. 
     The following example illustrates the present invention. Temperatures are in °C. unless otherwise noted. 
    
    
     EXAMPLE 1 
     Step A: 3,4-Dihydro-3(L)-(1H-indol-3-ylmethyl)1H-1,4-benzodiazepine-2,5-dione, A 
     L-Tryptophan (4.08 g, 20 mmole) and isatoic anhydride (3.26 g, 20 mmole) were suspended in a solution of triethylamine (2.8 ml, 20 mmole) in water (20 ml) and stirred at room temperature for 16 hours. The solvent was removed in vacuo (water aspirator, 80° C. bath). Acetic acid (60 ml) was added and the reaction was heated to reflux for 4 hours. Solvent was removed under reduced pressure (water aspirator, 80° C. bath) and the residue was dissolved in methanol (75 ml). Diethyl ether was added until the solution turned cloudy (125 ml). Crystallization ensued during several days of stirring at room temperature. The crude product was collected and washed with diethylether giving a tan solid (3.46 g). Chromatography (silica gel; 5% MeOH in CH 2  Cl 2 ) afforded the benzodiazepine A as a light tan solvate. Pure product A was obtained by drying in vacuum (0.01 mm, 150° C.). m.p. 247°-8.5° C. 
     Step B: 1,2,3,4-Tetrahydro-3(L)-(1H-indol-3-yl-methyl)-2-thioxo-5H-1,4-benzodiazepine-5-one, B 
     To a suspension of 5.93 g (19.42 mmole) of 3,4-dihydro-3(L)-(1H-indol-3-ylmethyl)-1H-1,4-benzodiazepine-2,5-dione in 75 ml of dry tetrahydrofuran was added 4.71 g (11.65 mmole) of 2,4-bis-(4-methoxyphenyl)-2,4-dithioxo-1,3,2,4-dithiadiphosphetane (Lawesson&#39;s reagent). The reaction mixture was protected from moisture and stirred at room temperature for 2 hours. The resulting clear solution was then partitioned between ethyl acetate and water. The organic phase was washed with 10% sodium hydroxide solution and brine, then dried (MgSO 4 ) and concentrated. The residual semi-solid was purified by flash chromatography on silica gel (hexane-ethyl acetate elution 1:2 v/v) to afford 2.04 g of the desired product B. m.p. 236°-237° C.; MS (20 ev), 321 (M + ), 192, 130; IR (KBr, partial) 3340, 1660, 1395, 1155, 760 cm -1  ; &#39;HNMR (CD 3  OD) 3.25 (1H, brs), 3.50 (1H, brs), 4.35 (1H, brs), 6.94 (1H, t, J=8), 7.05 (1H, t, J=8), 7.11 (1H, brs), 7.22 (1H, d, J=8), 7.30 (1H, d, J=8), 7.32 (1H, t, J=8), 7.38 (1H, d, J=8), 7.57 (1H, t, J=8), 7.79 (1H, brs), 7.81 (1H, brs). 
     Elem. Analysis Calc. for C 18  H 15  N 3  OS: N, 13.07; C, 67.27; H, 4.70. Found: N, 13.39; C, 67.39; H. 4.62. 
     Step C: 1,3-Dihydro-3(L)-(1H-indol-3-ylmethyl)-2-(methylthio)-5H-1,4-benzodiazepine-5-one, C 
     1,2,3,4-Tetrahydro-3(L)-(1H-indol-3-ylmethyl)-2-thioxo-5H-1,4-benzodiazepine-5-one (707 mg, 2.20 mmole) was dissolved in 18 ml of toluene:THF (2:1). To this solution was added 3 ml of 20% sodium hydroxide solution and 713 mg (2.10 mmole) of tetra-n-butyl ammonium hydrogensulfate. The reaction mixture was cooled to 0° C. with stirring and was then treated with iodomethane (137 μl, 2.20 mmole). After 10 minutes, the reaction mixture was roto-evaporated and the residue partitioned between ethyl acetate (100 ml) and water (50 ml). The organic phase was washed with water and brine, dried (MgSO 4 ) and concentrated to afford 900 mg of a foam C. Flash chromatography on silica gel (hexane-ethyl acetate elution, 1:1 v/v) afforded the analytical sample of C: &#39;HNMR (CDCl 3 ) δ 2.42 (3H, s), 3.25 (2H, m), 4.0 (1H, m), 6.85 (1H, d, J 2), 7.0-7.65 (8H, m), 7.85 (1H, dxd, J=8,1), 8.35 (1H, brs). 
     Step D: 6,7 -Dihydro-7(L)-(1H-indol-3-ylmethyl)quinazolino[3,2-a][1,4]benzodiazepine-5,13-dione X 
     An intimate mixture of 1,3-dihydro-3(L)-(1H-indol-3-ylmethyl)-2-(methylthio)-5H-1,4-benzodiazepine-5-one (116.3 mg, 0.346 mmole) and anthranilic acid (474.4 mg, 3.46 mmole) was immersed in a preheated oil bath at 175° C. for 50 minutes. Excess anthranilic acid was sublimed from the reaction vessel under reduced pressure and the residual melt was cooled and triturated with ether. The resulting tan solid was collected and chromatographed on silica gel (chloroform-methanol-concentrated ammonia elution, 95:5:0.5 v/v) to afford 75 mg of the title compound X. Recrystallization from methylene chloride-methanol afforded white stars identical in all respects (MS, IR, &#39;HNMR,  13  CNMR, and mp) with the authentic material (cf published European patent application No. 116150). 
     Claims to the invention follow.